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Objective: To carry out a systematic review of the literature addressing cognitive func-
tions in first-episode psychosis (FEP), divided into domains. Although this is not a full
“cognitive-genetics-in-schizophrenia review,” we will also include putative ideas of mecha-
nism(s) behind these impairments, focusing on how early stress, and genetic vulnerability
may moderate cognitive function in psychosis.
Method: Relevant studies were identified via computer literature searches for research
published up to and including January 2013, only case-control studies were included for
the neurocognitive meta-analysis.
Results: Patients with FEP present global cognitive impairment compared to healthy con-
trols.The largest effect size was observed for verbal memory (Cohen’s d effect size=2.10),
followed by executive function (effect size=1.86), and general IQ (effect size=1.71).
However, effect sizes varied between studies.
Conclusion: Cognitive impairment across domains, up to severe level based on Cohen’s
effect size, is present already in FEP studies. However, differences in levels of impair-
ment are observed between studies, as well as within domains, indicating that further
consolidation of cognitive impairment over the course of illness may be present. Cognitive
abnormalities may be linked to a neurodevelopmental model including increased sensitivity
to the negative effect of stress, as well as genetic vulnerability. More research on this field
is needed.
Keywords: cognition, first-episode psychosis, stress, physiological, genes×environment interactions, review of
literature
INTRODUCTION
With an increased awareness of the extent of cognitive impair-
ments present in schizophrenia, cognitive dysfunction is now
viewed by many as a core abnormality of the disorder (1, 2).
The majority of patients with schizophrenia function at a cog-
nitive level of at least one standard deviation below that of healthy
comparison groups (3, 4). Together with a global impairment
in cognitive function, specific domains show greater dysfunc-
tion, such as episodic memory, working memory, and executive
function (5, 6). There are also patients with schizophrenia with
cognitive scores in the normal or above-normal range, varying in
different studies from 15 to 45% (6–10). Nevertheless, in the high
cognitive function subgroup, 64% still have abnormal scores on at
least one cognitive domain, compared to 35% of healthy controls
(7). Here a profile is considered abnormal if at least two functions
are more than two SDs below the normative mean, or if only a
single function is extremely impaired [i.e.,>3 SDs below the nor-
mative mean (6)]. Therefore, most of the high functional group
demonstrates some kind of cognitive deficit compared to healthy
controls.
Investigating cognitive performance in patients at the early
stages of the illness has the advantage of identifying cognitive
deficits more likely to reflect the neurodysfunction that under-
lies schizophrenia rather than possible illness or treatment related
processes following the chronic course of the illness. Of course, it is
still possible that prodromal symptoms, or even very short periods
of psychotic symptoms, lead to cognitive changes, but investigat-
ing patients at illness onset can give new insight into the disorder,
when compared to the large amount of research that has been con-
ducted in long-term ill patients. Moreover, these studies can also
help elucidate whether or not some of the cognitive changes are
a consequence of long-term pharmacological treatment. In con-
sidering studies in patients with first-episode psychosis (FEP), it is
important to note that some have included not just patients with
schizophrenia, but also those with other psychoses. This is relevant
since during this early phase diagnosis may change (11), and not
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including such cases would mean losing potential schizophrenia
cases. It can also elicit different cognitive profiles based on the
heterogeneity of the first-episode group. For example, affective
psychosis may have better cognitive profile than a non-affective
schizophrenia (12).
Two recent articles have reviewed cognitive function during
the course of schizophrenia and other psychosis (prodromal, first-
episode, and chronic illness) (13, 14). However these have a very
broad scope. Instead, we decided to carry out a systematic review
of cognitive function in FEP; by focusing our review we were able
to go into greater depth to elicit patterns of sub area of impair-
ment measured by effect sizes. Compared to the review article
by Mesholam-Gately et al. (15), effect sizes were calculated based
on controls performance from the same catchment area as the
patients, thus avoiding differences in possible sample group biases
independent of psychosis. This is the first review article to present
in detail effect sizes comparing (subtypes) of FEP and controls
on cognitive performance, divided into domains. We will also
include putative mechanisms behind these impairments, and both
environmental and genetic factors will be discussed.
Only case-control studies were included for the neurocognitive
meta-analysis.
Further, we have included all types of FEP, not only schizophre-
nia (15), giving the possibility to compare “first-episode schizo-
phrenia” versus “other psychosis” on cognitive profile at start of
their first-episode of psychosis. We will also investigate if underly-
ing cognitive factors are driving the overall cognitive performance.
Finally, we will discuss possible etiological aspects, specifically
genetic and environmental factors, and how they interact.
Thus, the aim of this literature review is to present in detail
effect sizes comparing FEP and controls from the same catchment
area on cognitive performance divided into cognitive domains;
1) investigate and discuss if specific underlying cognitive fac-
tors are driving the overall cognitive function, as well as links to
disease progression; 2) discuss putative mechanisms behind our
findings including sensitivity to stress, and gene environmental
interactions.
METHODS
COGNITIVE FUNCTION IN FIRST-EPISODE PSYCHOSIS
A systematic review of the literature on cognition in FEP was con-
ducted. Medline (PubMed) and PsycINFO bibliographic databases
were used to search for articles reviewed. The search strategies
involved the following keywords: “cognition and schizophrenia,”
“cognitive function and schizophrenia,”cognitive function in FEP,”
and “cognition in first- episode psychosis,” up to and including
published papers June 2013. Criteria for inclusion were FEP, with
cognitive measures (data on mean± SD) for both patients and
controls. Twenty-four articles fulfilled these criteria’s. The qual-
ifying studies are presented in Tables 1–5, which include, for
each cognitive domain area, the bibliographic reference, the cog-
nitive tests used, and the degree of the impairment identified.
Effect sizes were computed using Cohen’s d (16). According to
Rosenthal and Rosnow (17), effect sizes were considered small for
values between 0.20 and 0.50, moderate for values between 0.50
and 0.80, and large for values greater than 0.80. The effect sizes
reflect those reported in the original published studies. For papers
that did not report the effect size, the effect size was calculated
on the basis of the mean and SD in the patient and the control
groups.
GENERAL INTELLECTUAL FUNCTION
General cognition is usually assessed in two ways. Firstly, general
cognitive ability is measured by a set of multiple cognitive tests
such as the Wechsler Adult Intelligence scale (WAIS). The WAIS is
based on multiple performance and verbal cognitive tests, which
together are believed to reflect general cognitive function. Sec-
ondly, general cognition is assessed with a single reading test, such
as the National reading test (NART) (3) or the Wechsler Test of
Adult Reading test (WTAR). The NART and the WTAR are read-
ing tests which both estimate cognitive ability by reading a list of
words, with the IQ level estimated on the basis of mistakes made
in the pronunciation of the words listed (38). In the literature on
FEP studies, the NART or the WTAR (or equivalent schedules) are
normally used to assess pre-morbid intelligence, an estimate of
intelligence level achieved before illness onset, while the WAIS is
usually used as an estimate of current IQ (12).
EXECUTIVE FUNCTION, ATTENTION, ANDWORKING MEMORY
The term “executive functioning” is often used as a synonym for
frontal lobe functioning, and to indicate higher cognitive function-
ing of the prefrontal cortex (2, 38). Executive function consists of
loosely related higher-order cognitive processes, including: prob-
lem solving, planning, initiation, hypothesis generation, cognitive
flexibility, decision making, regulation, and judgment and working
memory (38). Working memory is conceived as a limited capacity
storage for retaining information over a short time (1–2 min), and
performing mental operations of the content during this period
(38). Moreover, the context of the working memory may originate
from both sensory inputs as well as from stored long-term mem-
ory (38). Attention can be defined as the gateway for information
flow to the brain. Attention is a complex system that allows the
individual to filter relevant and irrelevant information in the con-
text of internal drives and intentions, hold and manipulate mental
processes, and monitor responses to stimuli (38).
MEMORY
Memory is a complex process by which an individual registers
retains and retrieves information (38). Memory is divided into
non-verbal and verbal memory, with verbal memory includ-
ing declarative memory and non-declarative memory. Declar-
ative memory includes both episodic memory (memory for
events) and semantic memory (memory for facts). Declarative
memory includes an understanding of something being learned,
while non-declarative memory can take place without conscious
awareness (38).
Several tests are used to assess memory, and the Wechsler Mem-
ory Scale (WMS) Logical memory test has been widely used to
assess declarative memory in psychosis. In the logical memory
task, the participant is asked to recall a short story, immediately
after hearing the story, and again after a delay of 30 min (38). Other
widely used verbal memory tasks in psychosis research are the Rey
Auditory Verbal Learning Test (RAVLT) and the California Verbal
Learning Test (CVLT), assessing memory functioning through the
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Table 1 | Studies comparing patients with first-episode psychosis and healthy controls on general cognitive ability.
Cognitive domain meta-analytic study Study variable Effect size
Hill et al. (18) Wechsler scales IQ Matched for IQ
Leeson et al. (19) Wechsler scales IQ Matched for IQ
Bilder et al. (3) Wechsler scales (performance IQ) 1.50
Bilder et al. (3) Wechsler scales (verbal IQ) 1.53
Bilder et al. (3) Wechsler scales IQ (performance and verbal subtests) 1.71
Chan et al. (20) Wechsler scales IQ (performance and verbal subtests) 0.29
Aas et al. (21) Wechsler scales IQ (performance and verbal subtests) 1.19
Zanelli et al. (12) Wechsler scales IQ (performance and verbal subtests) 0.66 All FEP
Zanelli et al. (12) Wechsler scales IQ (performance and verbal subtests) 1.52 SCH
Zanelli et al. (12) Wechsler scales IQ (performance and verbal subtests) 0.53 Other psychosis
Leeson et al. (19) Pre-morbid IQ 0.39
Joyce et al. (22) Pre-morbid IQ 0.50
Mathes et al. (23) Pre-morbid IQ 1.05
Zanelli et al. (12) Pre-morbid IQ 0.54 All FEP
Zanelli et al. (12) Pre-morbid IQ 0.79 SCH
Zanelli et al. (12) Pre-morbid IQ 0.45 Other psychosis
Bilder et al. (3) Pre-morbid IQ 1.00
Aas et al. (21) Pre-morbid IQ 1.09
Hermens et al. (24) Pre-morbid IQ 0.82
ALL FEP= schizophrenia, bipolar disorders, depressive psychosis, psychosis NOS; SCH= schizophrenia.
use of a word-list learning paradigm, which includes an immediate
and delayed component similar to the Logical memory (38). Non-
verbal memory is assessed by tests evaluating the ability to recall a
specific visual design, including an immediate and delayed aspect,
with Visual Reproduction and the Rey–Osterrieth Complex Figure
Test being the most frequent tests used in the literature (38).
PROCESSING SPEED
Processing speed refers to the speed at which different cognitive
tasks are completed. It normally involves a simple task, which
is timed on completion. The importance of processing speed
lies in its relevance to many higher cognitive operations, such as
perceptual processes, encoding, and retrieval (38).
MOTOR SPEED
Deficits in motor performance are seen in many neurological
disturbances. The most frequently used motor tests in FEP are
grooved pegboard and finger tapping. The grooved pegboard
contains twenty-five holes with randomly positioned slots and
pegs which have a key along one side. Pegs must be rotated
to match the hole before they can be inserted as quickly as
possible. For the finger tapping task the examinee is instructed
to tap as rapidly as possible using index finger for a specific
amount of time. For both grooved pegboard and finger tapping




Overall, patients with FEP scored significantly worse on current IQ
assessed by the WAIS battery compared to controls (see Table 1).
The largest effect size across FEP studies was observed for the
WAIS full scale IQ (based on performance and verbal tasks from
the WAIS), with an effect size of 1.71 (3). Significant differences
between patients and controls have also been replicated in studies
using NART or WTAR scores to measure pre-morbid IQ. Thus
in our own work (21), we found a significant difference between
NART scores in patients and controls, with an effect size of 1.09.
Significant differences between patients and controls NART scores
are also shown in other studies, with effect sizes varying between
0.39 and 1.05.
EXECUTIVE FUNCTION, ATTENTION, ANDWORKING MEMORY
Patients with FEP show impairment in executive performance,
with effect sizes ranging from 0.25 to 1.86, with the most profound
deficits observed Mohamed et al. (1) on Wisconsin Card Sorting
Test (WCST) perseverative errors, with an effect size of 1.86 (see
Table 2). Working memory follows with an effect size up to 1.42,
followed by attention (effect size up to 1.30).
MEMORY
Several studies in FEP have shown significant impairments in
memory, particularly in verbal declarative episodic memory (see
Table 3). The effect sizes of verbal episodic memory deficits vary
from 0.26 to 2.10, and the effect sizes for non-verbal mem-
ory vary from 0.38 to 1.65. As shown by the high effect size
reported from studies on FEP, memory impairment is the most,
or one of the most, impaired cognitive domains already at illness
onset.
PROCESSING SPEED
Studies of patients with FEP have shown reduced processing speed
in these patients when compared to controls, with effect sizes
ranging from 0.33 to 1.69 (see Table 4).
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Table 2 | Studies comparing patients with first-episode psychosis and healthy controls on executive function, attention and working memory.
Cognitive domain meta-analytic study Study variable Effect size
EXECUTIVE FUNCTION
Mohamed et al. (1) Fluency (total) 0.75
Rodriguez-Sanchez et al. (25) Fluency (total) 0.86
Ngoma et al. (26) Fluency (total) 0.76
Zabala et al. (27) Fluency (total) 0.82
Addington and Addington (28) Semantic fluency 1.02
Addington et al. (29) Semantic fluency 1.16
Ma et al. (30) Semantic fluency (several measures) 0.55–0.58
Chan et al. (20) Semantic fluency 0.71
Pena et al. (31) Semantic Fluency 1.49
Addington et al. (29) Phonemic fluency 0.44
Addington and Addington (28) Phonemic fluency 0.57
Pena et al. (31) Phonemic fluency 1.57
Brickman et al. (32) Trail making test part B 1.10
Ma et al. (30) Trail making test part B 0.79
Addington and Addington (28) Trail making test part B 0.97
Addington et al. (29) Trail making test part B 0.82
Chan et al. (20) Trail making test part B 0.33
Rodriguez-Sanchez et al. (25) Trail making test part B 1.07
Ngoma et al. (26) Trail making test part B 0.80
Aas et al. (21) Trail making test part B 1.19
Hermens et al. (24) Trail making test part B 1.10
Perez-Iglesias et al. (33) Trail making test part B 1.23
Gonzalez-Blanch et al. (34) Trail making test part B 1.05
Gonzalez-Blanch et al. (35) Trail making test part B 1.16
Mohamed et al. (1) Trail making test* 1.41
Zabala et al. (27) Stroop–color word interference 0.62
Ma et al. (30) Stroop–color word interference 0.53
Gonzalez-Blanch et al. (35) Stroop–color word interference 0.57
Mohamed et al. (1) Stroop–color word interference 0.29
Ngoma et al. (26) Stroop–color word interference 0.25
Zabala et al. (27) Stroop (several measures) 0.96–1.28
Pena et al. (31) Stroop color word test 1.56
Ma et al. (30) Executive functions (range in reported subgroups) 0.40–0.69
Leeson et al. (19) Executive function (general) 0.40
Liu et al. (36) MSET total 1.06
Addington et al. (29) WCST categories 0.53
Ma et al. (30) WCST categories 0.61
Addington and Addington (28) WCST categories 0.64
Chan et al. (20) WCST categories 0.61
Pena et al. (31) WCST categories 0.81
Ngoma et al. (26) WCST categories 0.86
Liu et al. (36) MWCST categories 0.98
Addington et al. (29) WCST perseverative errors 0.62
Mohamed et al. (1) WCST perseverative errors 1.86
Mohamed et al. (1) WCST perseverative errors 0.75
Pena et al. (31) WCST perseverative errors 0.51
Addington and Addington (28) WCST perseverative errors 0.79
Ma et al. (30) WCST perseverative errors 0.87
Zabala et al. (27) WCST perseverative errors and errors (several measures) 0.80–0.96
(Continued)
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Table 2 | Continued
Cognitive domain meta-analytic study Study variable Effect size
Chan et al. (20) WCST perseverative errors 0.64
Liu et al. (36) MWCST perseverative errors 1.11
WORKING MEMORY
Leeson et al. (19) Spatial span (several tests) 0.42–0.49
Addington et al. (29) Letter-number span 1.00
Gonzalez-Blanch et al. (35) Letter-number sequencing test 0.80
Pena et al. (31) Letter-number sequencing task 1.42
Ngoma et al. (26) Letter-number sequencing task 1.42
Zabala et al. (27) Letter-number sequencing task 0.66
Mohamed et al. (1) Digit span total 0.55
Ma et al. (30) Digit span total 0.81
Joyce et al. (22) Spatial working memory CANTAB 1.11
Aas et al. (21) Spatial working memory (CANTAB) several tests 0.94–1.01
MAINTENANCE
Zabala et al. (27) Digit span forwards 0.84
MAINTENANCE+MANIPULATIONS
Gonzalez-Blanch et al. (34) Digit span backwards 1.03
Pena et al. (31) Digit span backwards 1.11
Zabala et al. (27) Digits span backwards 0.84
Ma et al. (30) Arithmetic 0.77
Leeson et al. (19) Arithmetic 0.22
ATTENTION
Zabala et al. (27) Continuous performance test 0.44
Zabala et al. (27) Continuous performance test 0.61
Kleinlogel et al. (37) Continuous performance test 0.82
Mohamed et al. (1) Continuous performance test 1.56
Perez-Iglesias et al. (33) Continuous performance test 0.95
Gonzalez-Blanch et al. (35) Attention tests (several tests) 0.64–1.42
Rodriguez-Sanchez et al. (25) Attention index 1.30
Ngoma et al. (26) Attention index 1.22
Bilder et al. (3) Attention index 1.15
Addington and Addington (28) Attention test (Span) 0.07
Addington et al. (29) Attention tests (several) 0.29–0.39
Chan et al. (20) Attention test 0.48
Joyce et al. (22) Attention set shifting CANTAB 0.52
WCST, Wisconsin card sorting test; MSET, modified six elements test; MWCST, modified Wisconsin card sorting test; trail making test time, not specified whether
this is Trail A or Trail B.
MOTOR SPEED
Patients with FEP show impairments on motor speed (with effect
sizes varying from 0.36 to 1.26; see Table 5).
DISCUSSION
Reviewing the literature on cognitive function in FEP, we found
significant impairment (Cohen’s d effect size above 0.8 (17) in all
cognitive domains investigated; see Tables 1–5. The largest effect
size was observed for verbal memory (Cohen’s d effect size= 2.10),
followed by executive function (effect size= 1.86), and general IQ
(effect size= 1.71). Our systematic review focused on FEP and
included studies published up to 2013, thus covering studies not
included previously in the review by Bozikas and Andreou (13)
(included studies up to January 2010); or Lewandowski et al. (14)
(included studies up to 31st of March 2010). Moreover, the study
by Bozikas and Andreou (13) included only articles with longitu-
dinal data, excluding studies presenting FEP only. Also the study
by Lewandowski et al. (14) included articles on cognitive function
in chronic schizophrenia and other psychosis. Our study therefore
complements these articles, focusing in-depth on the first-episode
only. We have also calculated effect sizes based on Cohen’s d, pro-
viding information about the severity of the impairment, which
is not included in the previous reviews described above. Simi-
lar to the study of Bozikas and Andreou (13) and Lewandowski
et al. (14) we found that already at illness onset patients with
FEP are characterized by cognitive impairments across domains.
Moreover, our results support different cognitive pattern for schiz-
ophrenia and affective psychosis (schizophrenia patients showing
the greatest effect size differences in cognitive performance com-
pared to controls). Further, we found more variation in the effect
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Table 3 | Studies comparing patients with first-episode psychosis and healthy controls on memory function.
Cognitive domain meta-analytic study Study variable Effect size
Hermens et al. (24) Immediate verbal memory (general) 1.81
Zabala et al. (27) Immediate verbal memory (general) 1.62
Gonzalez-Blanch et al. (35) Immediate verbal memory (general) 0.81
Addington and Addington (28) Immediate verbal memory (general) 1.13
Ma et al. (30) Immediate verbal memory (general) 0.73
Hill et al. (18) Immediate verbal memory (general) 0.58
Chan et al. (20) Immediate verbal memory (general) 0.45
Aas et al. (21) Immediate verbal memory (general) 1.85
Ma et al. (30) Immediate verbal memory (general) 0.46
Addington et al. (29) Immediate verbal memory (general) 2.10
Mohamed et al. (1) Immediate verbal memory (general) 1.34
Rodriguez-Sanchez et al. (25) Verbal memory (both immediate and delayed) 0.80
Bilder et al. (3) Verbal memory (both immediate and delayed) 1.63
Brickman et al. (32) Learning 1.79
Hermens et al. (24) Learning 1.34
Leeson et al. (19) Learning 0.61
Ngoma et al. (26) Learning 1.14
Addington et al. (29) Learning 1.63
Addington and Addington (28) Learning 0.26
Zabala et al. (27) Learning 1.47
Mohamed et al. (1) Delayed verbal memory (general) 1.28
Mohamed et al. (1) Delayed verbal memory (general) 1.22
Addington et al. (29) Delayed verbal memory (general) 1.49
Addington et al. (29) Delayed verbal memory (general) 1.55
Hill et al. (18) Delayed verbal memory (general) 0.55
Addington and Addington (28) Delayed verbal memory (general) 0.99
Addington and Addington (28) Delayed verbal memory (general) 1.26
Ma et al. (30) Delayed verbal memory (general) 0.82
Chan et al. (20) Delayed verbal memory (general) 0.64
Gonzalez-Blanch et al. (35) Delayed verbal memory (general) 0.72
Aas et al. (21) Delayed verbal memory (general) 1.90
Pena et al. (31) Delayed verbal memory (general) 1.44
Hermens et al. (24) Delayed verbal memory (general) 1.50
Perez-Iglesias et al. (33) Delayed verbal memory (general) 0.75
Zabala et al. (27) Delayed verbal memory (general) 1.54
MEMORY–NON-VERBAL
Mohamed et al. (1) Immediate non-verbal memory 0.85
Aas et al. (21) Immediate non-verbal memory 0.68
Addington et al. (29) Immediate non-verbal memory 0.38
Addington and Addington (28) Immediate non-verbal memory 0.86
Bilder et al. (3) Non-verbal memory index 1.65
Aas et al. (21) Delayed non-verbal memory 0.39
Ma et al. (30) Delayed non-verbal memory 0.48
Mohamed et al. (1) Delayed non-verbal memory 0.92
RECOGNITION
Mohamed et al. (1) Recognition 1.70
Hill et al. (18) Recognition 0.58
Aas et al. (21) Recognition 1.56
sizes comparing patients and controls on cognitive tests than the
study by Reichenberg et al. (2) in chronic schizophrenia, indicat-
ing a further consolidation of cognitive impairment over time may
be present. These results are similar to Bozikas and Andreou (13)
and Lewandowski et al. (14) showing the main reduction in cogni-
tion around illness onset, or pre-morbid period, with a relatively
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Table 4 | Studies comparing patients with first-episode psychosis and






Addington and Addington (28) Trail making test part A 1.14
Ma et al. (30) Trail making test part A 0.76
Brickman et al. (32) Trail making test part A 0.95
Addington et al. (29) Trail making test part A 0.96
Chan et al. (20) Trail making test part A 0.45
Aas et al. (21) Trail making test part A 1.11
Gonzalez-Blanch et al. (34) Trail making test part A 0.70
Pena et al. (31) Trail making test part A 1.33
Zabala et al. (27) Trail making test part A 0.77
Hermens et al. (24) Trail making test part A 1.01
Ngoma et al. (26) Trail making test part A 0.33
Gonzalez-Blanch et al. (35) Trail making test part A 1.07
Ma et al. (30) Digit symbol coding 1.45
Gonzalez-Blanch et al. (34) Digit symbol coding 1.69
Mohamed et al. (1) Digit symbol coding 1.69
Table 5 | Studies comparing patients with first-episode psychosis and






Addington and Addington (28) Pegboard (dominant) 0.72
Addington et al. (29) Pegboard (dominant) 0.76
Perez-Iglesias et al. (33) Pegboard (dominant) 1.01
Addington et al. (29) Pegboard (non-dominant) 0.90
Addington and Addington (28) Pegboard (non-dominant). 0.79
Rodriguez-Sanchez et al. (25) Finger tapping left and right hand 0.89
Ngoma et al. (26) Finger oscillation task 1.26
Brickman et al. (32) Finger tapping test, left hand 0.36
Mohamed et al. (1) Finger tapping test, left hand 0.62
Brickman et al. (32) Finger tapping test, right hand 0.51
Mohamed et al. (1) Finger tapping test, right hand 0.79
stable course, which may become even more pronounced after
some years.
Our findings in FEP demonstrate that already at illness onset
patients have reduced IQ scores compared to controls. Both cur-
rent IQ and estimated pre-morbid IQ were significantly lower
than those of controls, with the greatest impairment in cur-
rent IQ scores. Indeed, the discrepancy between current IQ and
pre-morbid scores is believed to reflect the deterioration in cur-
rent IQ at or around illness onset. The study by Zanelli et al. (12)
show that when we examine schizophrenia versus other psychosis
(psychosis NOS and affective psychosis), patients with schizo-
phrenia have larger effect size differences in current IQ, as well
as pre-morbid IQ (schizophrenia current IQ effect size= 1.52;
pre-morbid IQ effect size= 0.79), compared to other psychosis
(current IQ effect size= 0.53; pre-morbid IQ effect size= 0.45).
This indicates worse cognitive function in the schizophrenia group
both at illness onset and prior to illness onset, compared to patients
with other psychosis. Patients in the schizophrenia group also
present the greatest deterioration (measured by effect size) com-
paring current IQ to pre-morbid IQ [schizophrenia effect size
current IQ (1.52) minus effect size pre-morbid IQ (0.79)= 0.73,
compared to other psychosis: effect size current IQ (0.53) minus
effect size pre-morbid IQ (0.45)= 0.08]. A worse cognitive profile
in patients with schizophrenia was also found in the study by Hill
et al. (39) showing that patients with FEP who developed schiz-
ophrenia demonstrated more impaired cognitive performance
across domains, compared to patients with affective psychosis.
Similar findings are also observed in chronic psychosis (14).
Several studies conducted in FEP have matched patients and
controls on general cognition, in order to investigate specific
deficits believed to be particularly marked in psychosis. It should
be mentioned that matching subgroups on IQ aiming to measure
specific cognitive areas believed to be impaired in psychosis may be
challenging due to that such a comparison would be contaminated
by regression toward the mean (Lord’s Paradox) (40).
EXECUTIVE FUNCTION, ATTENTION, ANDWORKING MEMORY
Although a strong correlation has been found between general
intellectual function and other specific cognitive subareas, such
as memory and executive functioning, research has also shown
impairment of executive functions, such as planning, flexibility
and judgment, without any major change in general intellectual
status (38). Is the impairment in executive and working mem-
ory observed in patients with psychosis a consequence of general
cognitive decline, or is executive impairment in psychosis indepen-
dent from overall cognitive performance? Chan et al. (20) aimed
to answer this question in a study of 78 patients with first-episode
medication-naïve schizophrenia and 60 controls; they showed that
patients with first-episode medication-naïve schizophrenia exhibit
specific types of executive dysfunction independently of general
cognitive decline. However, Table 2 shows that there is a great
discrepancy across studies in terms of effect sizes observed; for
example the effect size 0.22 was found for“Arithmetic” in the study
by Leeson et al. (19), compared to an effect size of 0.77 in the study
by Ma et al. (30). One difference between these two studies was
that the study by Leeson et al. (19) had matched the patients and
controls for general IQ, while the study by Ma et al. (30) had not.
It is therefore important to have in mind whether general IQ has
been taken into account in the analysis when interpreting effect
sizes for different cognitive subtests.
MEMORY
It has been suggested that episodic memory tests could be used
to elicit diagnostic differences in a psychosis sample. For exam-
ple, in the study by Fitzgerald et al. (41) consisting of 83 patients
with FEP, decreased performance on verbal memory was reported
in patients with schizophrenia compared to patients with affec-
tive psychosis, implying diagnostic differences in performance on
this specific memory task. Prospective studies also show worse
cognitive profile in patients with FEP who later develop schiz-
ophrenia across cognitive domains, compared to patients with
affective psychosis (12, 39).
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PROCESSING SPEED
The study by Leeson et al. (19), comparing FEP and healthy con-
trols (matched for general cognition) reported that processing
speed was the cognitive domain most impaired in FEP. Leeson
et al. (19) also found a relationship between processing speed per-
formance and performance on executive and memory tasks, two
known impaired cognitive domains in psychosis, as discussed ear-
lier. This indicates the importance of measuring processing speed
when studying patients with psychosis. As processing speed is
important for the performance of higher cognitive operations,
such as executive functions and memory, it has been suggested
that impaired processing speed underlies the abnormalities in
these areas (42). On the other hand, to complicate this further,
a reduction of processing speed has also been found associated
with antipsychotic medication (43).
Below are hypothesis about putative mechanism(s) of the cog-
nitive reduction in FEP, investigating the role of early stress,
inflammation and genetic vulnerability.
STRESS AND COGNITION IN PSYCHOSIS
Some previous studies in chronic patients with psychosis, and in
healthy controls, report a negative correlation between childhood
trauma and cognitive function, particularly decreased scores on
general cognitive abilities, memory, and executive function (44–
48). This is interesting as similar cognitive areas are found to be
most reduced in FEP, comparing patients to controls performance
(see Result). The deleterious effect of stress and glucocorticoid on
the brain (particularly on hippocampus) is well known in the lit-
erature (49, 50), and indeed disorders characterized by increased
stress exposure such as depression, post-traumatic stress disorder,
chronic fatigue disorder, show cognitive impairment, particularly
in memory and in executive function (51–53). Moreover, psychosis
is a disorder characterized by high level of stressful events (54),
including recent stressful events (55), the inability to cope with
life events (56, 57), and childhood trauma (58, 59). It is therefore
possible that some of the cognitive impairment in FEP is due to an
increased exposure, or vulnerability toward the negative effect of
particularly childhood trauma. We will now review the literature
supporting this putative mechanism.
CORTISOL LEVEL AND COGNITIVE FUNCTION AND PSYCHOSIS
Over two decades have past since the first study investigating
Hypothalamic-Pituitary-Adrenal (HPA) axis and cognitive abnor-
malities in schizophrenia were published (60) and suggested a link
between hypercortisolism and cognitive impairment. Since then,
several studies have investigated HPA axis and cognitive function
in long-term chronic schizophrenic patients. The first study by Saf-
fer et al. (60) consisted of 11 patients with type II schizophrenia
(mainly negative symptoms), 34 controls, 30 patients with schiz-
ophrenia with type 1 (mainly positive symptoms), and 9 patients
with mixed type I and type II schizophrenia (both negative and
positive symptoms). This study found a strong negative correla-
tion between dexamethasone abnormalities (dexamethasone non-
suppressors) and cognitive performance in type II schizophrenics,
implying a relationship between HPA axis hyperactivity and cog-
nitive impairment. Furthermore, Walder et al. (61), evaluating 18
patients with chronic psychosis, 7 patients without psychosis, and
19 healthy controls, found that, in the entire sample, cortisol lev-
els were negatively correlated with performance on memory and
executive tasks.
Also in FEP an abnormal HPA axis has been demonstrated
(55) showing higher cortisol levels during the day in the patients
compared to the controls. An interesting closed-loop model, first
hypothesized by Lupien (62), gives a possible explanation for the
relationship between cortisol level and cognition in schizophre-
nia. The closed-loop model works in the following manner: basal
cortisol level increases symptoms severity, which again impacts
on the encoding of incoming information into long-term mem-
ory store; this leads to difficulties discriminating between relevant
(threat) and irrelevant (non-threat) information, which again
further increases the reactivity to stress.
In our recent paper on patients with FEP (21), we found that
patients performed significantly worse on all cognitive domains
compared to controls. In patients only, a blunted cortisol awaken-
ing response (that is, more abnormal) was associated with a more
severe deficit in verbal memory and processing speed, supporting a
role for the HPA axis, as measured by cortisol awakening response,
in modulating cognitive function in patients with psychosis.
CHILDHOOD TRAUMA AND COGNITIVE FUNCTION IN PSYCHOSIS
Six studies in the literature have investigated cognition and early
trauma in people with psychosis, four in individuals including
chronic illness phase. The first study by Lysaker et al. (45) was
conducted in males with schizophrenia spectrum disorder, and no
comparison control group was used. The authors found that male
patients with childhood trauma (sexual abuse) had impaired pro-
cessing speed, working memory, and executive function compared
with patients without abuse (45). The second study by Schenkel
et al. (47) included 15 female and 25 males with schizophre-
nia spectrum disorder, with no comparison control group. The
authors found that patients with schizophrenia or schizoaffective
disorder with a history of childhood trauma showed a decreased
score on learning and visual context processing compared to
non-abused patients. Similar findings were found in the study
by Shannon et al. (48) in a sample of 85 patients (67 males and
18 females) with chronic schizophrenia; here patients with child-
hood trauma scored significantly lower on working memory as
well as verbal memory tasks, even after controlling for pre-morbid
IQ and depressive symptoms. Similar findings were observed in
our own examination of the large AESOP study of FEP which
comprised of 138 patients (73 males and 65 females) and 138 con-
trols (64 males and 74 females), showing an association between
childhood trauma and reduced performance on attention, con-
centration and mental speed, language, and verbal intelligence;
however this was mainly driven by male patients with affective
psychosis (44), whilst in controls only one subtest (performance
intelligence) was reduced in the group with high exposure of child-
hood trauma, and in males only. Also in an independent study
including 406 patients with a mean duration of illness of 3 years
showed a strong negative correlation between cognitive function
and a history of childhood trauma; here childhood trauma was
associated with a reduction in cognitive function across cognitive
domains in patients with schizophrenia spectrum- and bipolar
disorders, in particular working memory and executive function,
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as well as general cognition. Moreover, these dysfunctions were
driven by underlying deficits in general cognitive tasks as mea-
sured by the Wechsler Abbreviated Scale of Intelligence (WASI)
(63). Only two studies have found negative, or inconclusive, find-
ings between cognitive function and early trauma in FEP (21, 64),
with the latter and largest study showing an effect of childhood
trauma on cognitive function in controls, but not in patients (64).
POTENTIAL BIOLOGICAL MECHANISMS
Since patients with psychotic disorders – in addition to being
more exposed to trauma – also demonstrate abnormalities in the
HPA axis (55), immunological disturbances (65, 66), together with
cognitive and brain structure abnormalities (6, 12, 21, 67), it is of
interest to investigate the link between stress exposure and bio-
logical stress parameters to cognitive abnormalities in psychosis.
Based on the findings outlined above, it is particularly intrigu-
ing to investigate to what extent patients with psychotic disorders
also have a genetic vulnerability toward abnormal stress response
that may add to – or interact with the effects of early trauma, and
cognitive impairments.
There are several indications of an abnormal HPA axis in
patients with psychotic disorders irrespective of early trauma. This
includes findings of an increased pituitary volume in patients with
FEP compared to controls (68, 69). There are also signs of an
altered or increased systemic cortisol metabolism (70–72) with
links to genetic markers in psychosis (71), which might inter-
act with the effect of stressful life event. The idea of a genetic
predisposition to an abnormal stress response is supported by
indications that not only patients with psychosis have abnormal
stress responses, but also their relatives (73). Moreover, increased
cortisol levels correlate with smaller hippocampal volume in psy-
chosis (74). There is also an interaction between glucocorticoids
and serotonin in the central nervous system (CNS) as glucocor-
ticoids regulate both tryptophan hydroxylase and the expression
of several serotonin receptors (75). In addition, the functional
polymorphism in the promoter region of the serotonin trans-
porter gene (5-HTTLPR) has been linked to altered stress response,
as carriers of the short (s-) allele have increased negative psy-
chological reactions and stress hormone release compared with
carriers of the long (l-) allele (76). Indeed, our study Aas et al.
(76) demonstrated that patients with an early psychotic illness
who were carriers of the short (s-) allele of the serotonin trans-
porter gene (5-HTTLPR), exposed to high levels of childhood
trauma (physical neglect and abuse) had significantly poorer cog-
nitive functioning, than all other groups. Patients with psychosis
also show reduced brain-derived neurotropic factor (BDNF) levels
both in the brain (77), and in serum and plasma (77–79), which
may be related to their cognitive performance (80). The BDNF
gene has at least one functional variant, the SNP (rs 6265) result-
ing in a Valine (val) to Methionine (met) substitution at codon
66 of the proBDNF. The low active met allele is here related to
reductions in BDNF release (81). Recent research in FEP have
found associations between reduced BDNF gene expression lev-
els, childhood trauma, increased inflammation, and smaller hip-
pocampal volume (82). Reduced BDNF levels are also observed
in bipolar patients exposed to childhood trauma (83), as well as
linked to cognition in animals (84). It is well known that patients
with psychosis show brain structural abnormalities compared to
healthy controls (67, 85, 86). A recent meta-analyses in healthy
individuals indicate hippocampus volume reductions in met car-
riers compared to homozygotic val carriers (87); this is an area of
the brain important for memory. In psychosis, met carriers usu-
ally demonstrate larger ventricles, more CSF, and reduced frontal
gray matter volume (88, 89), even if there are inconsistent results
(90). While the study by Mondelli et al. (82) did not genotype,
their study support the role of BDNF on brain structures, as well
as a relationship between childhood trauma and BDNF levels.
Childhood trauma may thus represent a significant factor influ-
encing cognitive function in psychosis, mediated through an effect
on BDNF. Indeed our recent study in patients with a psychotic
illness (80) support this hypothesis, showing that BDNF val66met-
met carriers reporting high levels of childhood trauma demon-
strate significantly reduced executive function/working memory
as well as smaller hippocampal volume, compared to all other
groups.
Several lines of evidence have implicated the immune sys-
tem in the development of severe psychiatric disorders, and
increased inflammation is found in depression (91–93), as well
as in psychosis (65, 66, 94). Recent GWAS studies clearly indi-
cate immune genes as susceptibility genes for schizophrenia (92,
95). Increased inflammation is also found to be associated with
cognitive impairments in animals (96). Pilot data from a small
sample of patients with FEP and healthy controls show a rela-
tionship between increased inflammation parameters (IL-8 and
IL-6) and cognitive impairments across both groups (97), indi-
cating that immune markers may be related to cognitive function
in psychosis. More studies should investigate this further, aiming
to understand the cognitive reduction seen in FEP compared to
healthy controls.
EPIGENETIC RESEARCH RELATED TO SCHIZOPHRENIA RISK AND
COGNITIVE FUNCTION
Recent epigenetic research related to schizophrenia risk, links early
stress (hypoxia and perinatal stress) to methylation and altered
gene expression associated with behavior and cognitive changes
(98). Perinatal stress has also been found to be related to reduction
of Brain-derived neurotrophic factor (BDNF) in the brain of adult
rats (84). Riva et al. (84) also show that perinatal stress in male
rats is related to reduced performance on the object recognition
test in the adult rat. Riva linked the above to epigenetic changes,
explaining that perinatal stress increases methylation, which again
is related to a reduced transcript of BDNF, and cognitive changes.
Riva et al. (84) has also demonstrated that perinatal stress is asso-
ciated with reduced upregulation of BDNF on the forced swim
test in adult rats, linking this to impaired ability to cope under
stressful situations in rats exposed to perinatal stress. Finally, Riva
et al. (84) also found that epigenetic changes in response to stress
are seen across genes: methylome analysis in the prefrontal cor-
tex of rats exposed to perinatal stress showed that a large number
of genes (3,386 genes) were methylated differently from controls.
These included genes linked to bipolar disorders and schizophre-
nia, such as CACNA1C and DISC1, as well as the COMT gene.
Further research should therefore investigate links between early
stress, and epigenetic changes of relevant genes across genome,
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FIGURE 1 | Suggests that cognitive impairment in FEP is related to neurodevelopmental abnormalities. Figure 1 also postulate that stress, as well as
genetic vulnerability may be part of the complex etiology behind cognitive impairment in psychosis.
aiming to understand mechanisms behind cognitive abnormalities
in patients with FEP.
LIMITATIONS
This study has several limitations which should be acknowledged:
we decided to focus on only some aspects which may influence
cognitive function (i.e., stress, and interactions between stress and
genetic factors, as well as inflammation), and we did not have
the possibility to go into depth on other important aspects, such
as time of illness onset (early illness related to worse cognitive
function), possible gender differences (males lower performance),
the influence of antipsychotics and medication, and the dura-
tion of treatment. Although all these patients are FEP, the exact
level of treatment varied between the studies (see Supplemen-
tary Material for an overview of recruitment in the different
papers discussed). Moreover other environmental factors such as
cannabis have both been associated with increased risk of the ill-
ness, as well as influencing cognitive function, however due to
space and focus of the paper, we focused on the role of stress
and inflammation and genetics related to these factors as possible
explanation model. Only the Cohen’s d and not the confidence
intervals for the Cohen’s d are included in this study. However, we
have included in the Supplementary Material a detailed overview
of the studies included aiming to facilitate interpretations of the
findings. As already mentioned matching subgroups on IQ aim-
ing to measure specific cognitive areas believed to be impaired
in psychosis may also be challenging due to that such a compar-
ison may be influenced by regression toward the mean (Lord’s
Paradox) (40).
SUMMARY
We have demonstrated that cognitive impairment across domains
(up to and above severe level based on Cohen’s d effect size) is
present already at illness onset, as shown in FEP studies. However,
differences in levels of impairment are observed between studies, as
well as within domains, indicating that compared to chronic schiz-
ophrenia (2), a further consolidation of cognitive impairment over
time may be present.
The research into trauma, stress, and HPA axis disturbances
(including gene interactions) is one of the areas where we have
some knowledge about how specific environment and genetic fac-
tors influence cognition (Figure 1). Indeed, early stress may have
long-lasting changes on cognitive function by affecting expression
of relevant genes. This is the start of a new line of research aimed
at further understanding the complex etiology behind cognitive
abnormalities in psychosis. Based on published biological stud-
ies, we propose that some of these impairments may be due to
these subjects’ increased sensitivity to the negative effect of stress,
and genetic vulnerability, affecting the HPA axis, the immune
function, and neuroplasticity. More studies are needed aiming
to understand the complex etiology of cognitive impairments in
psychosis.
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